On the contrary, EMP1 has been shown to be involved in cancer progression, including ovarian cancer and pediatric leukemia [42, 43], which suggests that the anti-tumor or tumor-promoting action of EMP is dependent on the type of cancer. This evidence concerns the gene MAEA and ovarian carcinoma.